MDMB-FUBICA

MDMB-FUBICA is an indole-based synthetic cannabinoid that is presumed to be a potent agonist of the CB1 receptor and has been sold online as a designer drug.

It was first detected by the EMCDDA in Sweden in February 2015. It is often sold in e-liquid form for use in an electronic cigarette.

Side effects
MDMB-FUBICA's indazole analogue MDMB-FUBINACA has been linked to at least 1000 hospitalisations and 40 deaths as a consequence of intoxication as of March 2015.

Legality
MDMB-FUBICA is banned in Sweden.